Elizabeth Fox

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares et al. · The Lancet Oncology · 2019 · 1.7K citations · Full text

Medicine, Oncology, Metastasis +9

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

Yaël P. Mossé, Stephan D. Voss, Megan S. Lim et al. · Journal of Clinical Oncology · 2017 · 403 citations · Full text

Medicine, Oncology, Pharmacology +15

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren et al. · The Lancet Oncology · 2019 · 343 citations

Medicine, Oncology, Pharmacotherapy +17

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial

Kara L. Davis, Elizabeth Fox, Melinda S. Merchant et al. · The Lancet Oncology · 2020 · 336 citations · Full text

Medicine, Oncology, Pharmacology +16

NF1 plexiform neurofibroma growth rate by volumetric MRI

Eva Dombi, Jeffrey Solomon, Andrea Gillespie et al. · Neurology · 2007 · 200 citations

Medicine, Neurology, Pediatrics +17